Palisade Bio stops Phase 2 LB1148 trial early; topline data due H1 2023

PALISADE BIO, INC.

Enrolled 35 of 70 planned patients in Phase 2 PROFILE study for post-surgical adhesions; voluntarily halting further enrollment.
Of those, 31 completed first surgery and 9 completed second surgery (key inflection point for data).
Topline data from the 35 patients expected in first half of 2023.
Company designing a dose optimization study to refine dosing; enrollment anticipated in H1 2023.
CMO Herbert Slade stated collected data is sufficient for evaluation and to guide next steps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.